If you've searched for Mounjaro vs Ozempic side effects, you've probably found plenty of percentages and few explanations. The question sounds simple: which drug causes more side effects? The honest answer depends on how each study was built, who was enrolled, how long people were followed, and what dose they took. This post shows you how to read those adverse event tables so the comparison actually means something.
Mounjaro and Ozempic side effects look easy to compare in a trial table, but the study design changes the answer. Here's how to read the numbers.
Why the side effect table is harder to read than it looks
Every trial paper lists adverse events by treatment arm, with a placebo column usually beside the drug columns. That placebo column matters more than most readers expect. Headache, tiredness, and dizziness show up in people taking placebo too, so the useful question is how much higher the drug arm runs.
Three programs are worth knowing. SURPASS-2, published in the New England Journal of Medicine in 2021, compared tirzepatide directly with semaglutide 1 mg in adults with type 2 diabetes. SURMOUNT tested tirzepatide for obesity, and STEP tested semaglutide for obesity. Each one enrolled different people and used different designs.
Before you compare any two numbers, open the methods section of the original paper. Check the population, the trial length, and the dose in each arm. If those differ, the percentages aren't measuring the same thing.
Eating well on GLP-1 doesn't have to be complicated: get a nutrition plan made for your treatment.
Build my planGastrointestinal effects, the most common category
Nausea, diarrhea, vomiting, and constipation are the events people ask about most. Pay attention to how each paper groups them. Some report nausea and vomiting separately, while others combine them under one heading. A combined figure can look bigger or smaller than it really is.
The general pattern is consistent across these drugs. These effects tend to appear during dose escalation, are usually mild to moderate, and often ease over time. That's why prescribing plans raise the dose slowly, and why the titration schedule matters when you compare results.
For exact figures, go to the adverse events table in the paper and read the nausea and diarrhea percentages for each arm. The prescribing information for each drug also has an Adverse Reactions section that shows what the manufacturer reports.
What head-to-head data can and cannot tell you
SURPASS-2 is the comparison people cite most, and it's useful because both drugs were tested in the same trial. Setting a number from one study beside a number from another is a different exercise. Different populations, durations, and doses can shift results for reasons unrelated to the drug itself.
Discontinuation due to adverse events often tells you more about tolerability than raw incidence. Imagine drug A causes nausea in many people, but most feel better within a few weeks and stay on treatment. Drug B causes nausea in fewer people, yet those who get it quit the study. Drug B looks better on incidence but may be harder to live with. Compare discontinuation rates for each arm, then check the follow-up period the paper declares.
Dose matters as much as the brand name. Tirzepatide at one level and semaglutide at another tell you little about equivalent exposure. Tracking your own tolerability over several weeks can fill that gap, and the OzemPro team can help you think through what to note.
Less common events that appear in the warnings
Some events are rare in trials but still appear in the warnings. Acute pancreatitis is one. Both labels tell people to stop treatment if pancreatitis is suspected, and they describe severe abdominal pain that may spread to the back.
Gallbladder disease, including gallstones and cholecystitis, is also a warning in both labels. Acute kidney injury appears too, mainly because severe gastrointestinal losses can lead to dehydration. Hypoglycemia matters most when these drugs are combined with insulin or sulfonylureas.
Check the Warnings and Precautions section of the current label, since prescribing information changes often. The boxed warning about thyroid C-cell tumors also appears there.
Retinopathy and the speed of glucose control
In SUSTAIN-6, published in 2016, more people taking semaglutide had retinopathy complications than those on placebo. The increase was concentrated in people who already had retinopathy when the trial started, and the semaglutide label carries a warning about it.
Why this happened is not settled. The trial wasn't designed to explain the mechanism, so any explanation is still a hypothesis. If you have retinopathy, ask your doctor about an eye exam before starting treatment and keep those exams going during treatment.
Still planning meals by trial and error? Build a nutrition plan tailored to your GLP-1.
Build my planInjection site reactions, allergy signs, and events that also happen on placebo
Redness, itching, or swelling at the injection site is usually mild and passes on its own. Hypersensitivity reactions such as hives or angioedema are rarer. Swelling of the face, lips, or throat, or trouble breathing, needs immediate medical care.
Headache, tiredness, and dizziness appear in the trials and in the placebo arm. Imagine an event that shows up in 10 percent of placebo users and 12 percent of drug users. That gap tells a very different story from one that climbs far higher on the drug. Read the gap in the table, not the drug percentage alone.
If a reaction feels unusual, write it down with the date and bring it to your prescriber. OzemPro can be a useful place to keep those notes together.
Turning the numbers into questions for your doctor and a simple log
Once you've read the tables, bring questions to your appointment. What is my baseline risk for pancreatitis or gallbladder disease? Which dose makes sense for me, and how fast should it rise?
Does a history of pancreatitis, gallstones, or kidney problems change the plan? Your answers depend on your own health, not on the average trial participant.
Writing things down makes these talks more useful. Note the date, your dose, each symptom, how severe it was, what you ate, and how much fluid you drank. Keep a simple symptom log for a few weeks, and you may see whether nausea tracks with meal size or hydration. A trial table can't show you that.
Some symptoms need urgent contact rather than a wait for the next appointment:
- Persistent vomiting or inability to keep liquids down
- Severe abdominal pain that spreads to your back
- Yellowing of the skin or the whites of the eyes
This article informs and does not replace a medical evaluation. Your prescriber knows your history, your other medicines, and your goals, so they are the right person to interpret these numbers for you.
FAQ
Does Mounjaro cause more side effects than Ozempic?
It depends on the study. SURPASS-2 compared the two directly in type 2 diabetes, while other trials used different populations and doses. Compare each drug against its own placebo arm rather than raw percentages from different papers.
Are nausea and diarrhea permanent?
Usually not. These effects tend to appear during dose increases and often ease over time. If they persist or get worse, talk with your prescriber about the dose and your fluid intake.
Why does the placebo arm matter so much?
Some side effects, such as headache and tiredness, also happen in people taking placebo. The difference between the arms shows how much of an event is likely linked to the medication.
Should I get an eye exam before starting these drugs?
If you already have diabetic retinopathy, ask your doctor about an eye exam before starting and during treatment. SUSTAIN-6 reported more retinopathy complications with semaglutide in people who already had retinopathy.
Sources
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2), New England Journal of Medicine, 2021
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6), New England Journal of Medicine, 2016
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), New England Journal of Medicine, 2021
- Ozempic (semaglutide) prescribing information, Novo Nordisk
- Mounjaro (tirzepatide) prescribing information, Eli Lilly
- Drugs@FDA, U.S. Food and Drug Administration
Aviso: Este conteúdo é apenas informativo e não substitui orientação médica profissional. Consulte sempre seu médico antes de iniciar, alterar ou interromper qualquer tratamento.
